How should an elevated anti‑cardiolipin antibody be evaluated and managed?

Evaluation and Management of Elevated Anti-Cardiolipin Antibody

An isolated elevated anti-cardiolipin antibody requires comprehensive testing with all three antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin, and anti-β2GPI) performed concurrently, followed by mandatory repeat testing at least 12 weeks later to confirm persistence before making any clinical decisions. 1

Initial Laboratory Evaluation

When anti-cardiolipin antibody is detected, immediately order the complete antiphospholipid antibody panel:

• Lupus anticoagulant (LA) - using two phospholipid-dependent clotting assays (dRVVT and LA-sensitive APTT) 1
• Anti-cardiolipin antibodies (aCL) - both IgG and IgM isotypes
• Anti-β2 glycoprotein I antibodies (aβ2GPI) - both IgG and IgM isotypes

All three tests should be performed on the same sample to accurately assess the antibody profile 1, 2. The aCL must be β2GPI-dependent to avoid detecting non-cofactor-related antibodies associated with infections or drugs 2.

Risk Stratification Based on Antibody Profile

The clinical significance varies dramatically based on the antibody profile:

Triple Positivity (Highest Risk)

• LA + aCL + aβ2GPI positive (concordant isotype)
• 90% of triple-positive patients present with clinical APS criteria 1
• Highest risk for first thrombotic event and recurrence 1
• Strong association with both thrombosis and pregnancy morbidity

Double Positivity (Moderate Risk)

• Typically LA negative with aCL and aβ2GPI positive (concordant isotype)
• 86% present with clinical APS criteria 1
• Moderate thrombotic risk

Single Positivity (Lower Risk)

• Isolated aCL alone has contradictory and disputed clinical relevance 1
• May reflect antibodies to cardiolipin itself rather than β2GPI 1
• Often associated with infections and has limited data in humans 1
• Isolated aCL carries significantly lower weight in the 2023 ACR/EULAR classification criteria 1

Critical caveat: Isolated aβ2GPI shows no association with thrombosis and is directed against epitopes not determining LA activity 1. However, isolated LA has high predictive value and receives high weight in classification criteria 1.

Isotype Considerations

IgG vs IgM

• IgG isotype has stronger association with thrombosis than IgM 2, 3
• IgM has more established role in pregnancy morbidity 2, 3
• For thrombotic APS evaluation, IgM testing adds no independent value 3
• For obstetric APS, IgM testing is warranted - isolated IgM occurs in 5.7-12.3% of obstetric APS cases 3

IgA Testing

The significance of IgA aCL remains controversial and is not currently recommended for routine testing 2.

Mandatory Repeat Testing

Positive results must be confirmed on repeat testing no less than 12 weeks after initial detection 1, 2. This requirement exists because:

• Transient antibodies occur with infections and drugs 1
• 96% of patients show extended persistence beyond 3 months in median follow-up of 56 weeks 1
• Single point results have limited utility given high inter-laboratory variation 4

Interpreting Antibody Levels

• Results above the 99th percentile should be regarded as positive 2
• The 2023 ACR/EULAR criteria set moderate and high titer thresholds at 40 U and 80 U respectively 1
• Lower antibody levels may be clinically relevant in pregnancy morbidity settings 2
• High inter-assay variability exists between commercial assays 2

Clinical Context Assessment

Evaluate for:

• Thrombotic events: venous or arterial thrombosis
• Pregnancy morbidity: unexplained fetal loss ≥10 weeks, premature birth <34 weeks due to eclampsia/placental insufficiency, or ≥3 unexplained consecutive miscarriages <10 weeks
• Autoimmune diseases: particularly systemic lupus erythematosus
• Recent infections or drug exposures that could cause transient positivity

Common Pitfalls to Avoid

1. Do not diagnose APS based on isolated aCL alone - the clinical relevance is disputed and requires correlation with other aPL 1
2. Do not skip repeat testing - transient positivity is common and does not indicate APS 1, 2
3. Do not ignore inter-laboratory variability - consider testing in another laboratory using different reagents if high clinical suspicion exists 1
4. Do not test IgM in suspected thrombotic APS - it provides no independent association with thrombosis 3
5. Beware of anticoagulant interference - LA testing may be affected by anticoagulation therapy, but solid-phase aCL and aβ2GPI testing is not 5

When to Consider Additional Testing

If clinical suspicion remains high despite negative or equivocal results, consider:

• Retesting with different assay methods/reagents 1
• Testing for antiphosphatidylserine/prothrombin antibodies (though not yet recommended for routine use) 2
• Collaboration between clinical pathologist and clinician for result interpretation 2